By Gina Shaw
Treatment with the optimized nano-scale liposomal formulation of cytarabine and daunorubicin, known as CPX-351 (Vyxeos, Celator Pharmaceuticals), reduced the risk for death by 31% compared with the standard cytarabine and daunorubicin (7+3) regimen in older patients with secondary acute myeloid leukemia (AML), according to Phase III data released by the drug’s developer. The result was the first in decades to show a significant survival improvement over standard of